Source comparison
Tesamorelin Dosage Protocols: Clinical vs Research Applications
HIV-Associated Lipodystrophy (FDA-Approved) 2mg daily Once daily, evening Sterile water for injection IGF-1 every 8 weeks, visceral adipose tissue via CT or MRI every 12-16 weeks Ongoing (discontinue if no VAT reduction after 26 weeks) Gold standard protocol w
This comparison does not assign a generated winner or score.
- HIV-Associated Lipodystrophy (FDA-Approved)
- 2mg daily
- Once daily, evening
- Sterile water for injection
- IGF-1 every 8 weeks, visceral adipose tissue via CT or MRI every 12-16 weeks
- Ongoing (discontinue if no VAT reduction after 26 weeks)
- Gold standard protocol with established safety profile across 5+ years of post-approval data. Discontinuation rates due to adverse events remain below 12%.
- General Body Composition Research
- 1-2mg daily
- IGF-1 every 4-8 weeks, DEXA or bioimpedance for body composition monthly
- 12-26 weeks typical
- Dose titration from 1mg to 2mg over 4 weeks reduces injection site reactions by 35% vs starting at 2mg. Most researchers plateau IGF-1 response by week 8-12.
- Anti-Ageing/Wellness Protocols (Off-Label)
- 1mg daily
- IGF-1 every 12 weeks, glucose/HbA1c monitoring (GH can impair insulin sensitivity)
- Variable, often cycled 3-6 months on, 1-2 months off
- Higher discontinuation rate (20-25%) due to cost and injection burden vs clinical benefit. No large-scale trials support anti-ageing efficacy claims. Evidence is extrapolated from lipodystrophy studies.
- Athletic Performance Research (Prohibited by WADA)
- Not applicable
- Tesamorelin appears on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors). Use in competitive athletics constitutes doping and carries 2-4 year competition bans.